Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd has announced significant advancements in its ColoSTAT® cancer diagnostic technology, with the second generation ColoSTAT® Multiplex Alpha Kit showcasing superior analytical results over its predecessor. This breakthrough, confirmed by testing on 200 patient samples, promises not only improved performance but also a more straightforward and reproducible assay process. The company is now progressing towards the Beta Kit production, with the ultimate goal of commercialization and improved early cancer detection.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.